Impact of Medication Adherence on Virologic Failure in A5202: A Randomized, Partially Blinded, Phase 3B Study

In AIDS Clinical Trials Group A5202, participants who reported missing their medication within the past month or not providing adherence reports at both 8 and 24 weeks had 5 times the hazard of virological failure compared to more adherent participants. Adherence interventions should focus on such p...

Descripción completa

Detalles Bibliográficos
Autores principales: Parker, Robert A., Rabideau, Dustin J., Sax, Paul E., Tierney, Camlin, Daar, Eric S., Collier, Ann C., Losina, Elena, Freedberg, Kenneth A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2017
Materias:
Brief Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5434358/
https://www.ncbi.nlm.nih.gov/pubmed/28329243
http://dx.doi.org/10.1093/cid/cix176
_version_ 1783237033850830848
author Parker, Robert A.
Rabideau, Dustin J.
Sax, Paul E.
Tierney, Camlin
Daar, Eric S.
Collier, Ann C.
Losina, Elena
Freedberg, Kenneth A.
author_facet Parker, Robert A.
Rabideau, Dustin J.
Sax, Paul E.
Tierney, Camlin
Daar, Eric S.
Collier, Ann C.
Losina, Elena
Freedberg, Kenneth A.
author_sort Parker, Robert A.
collection PubMed
description In AIDS Clinical Trials Group A5202, participants who reported missing their medication within the past month or not providing adherence reports at both 8 and 24 weeks had 5 times the hazard of virological failure compared to more adherent participants. Adherence interventions should focus on such patients.
format Online
Article
Text
id pubmed-5434358
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-54343582017-05-22 Impact of Medication Adherence on Virologic Failure in A5202: A Randomized, Partially Blinded, Phase 3B Study Parker, Robert A. Rabideau, Dustin J. Sax, Paul E. Tierney, Camlin Daar, Eric S. Collier, Ann C. Losina, Elena Freedberg, Kenneth A. Clin Infect Dis Brief Report In AIDS Clinical Trials Group A5202, participants who reported missing their medication within the past month or not providing adherence reports at both 8 and 24 weeks had 5 times the hazard of virological failure compared to more adherent participants. Adherence interventions should focus on such patients. Oxford University Press 2017-06-01 2017-03-01 /pmc/articles/PMC5434358/ /pubmed/28329243 http://dx.doi.org/10.1093/cid/cix176 Text en © The Author 2017. Published by Oxford University Press for the Infectious Diseases Society of America. http://creativecommons.org/licenses/by-nc-nd/4.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (http://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact journals.permissions@oup.com.
spellingShingle Brief Report
Parker, Robert A.
Rabideau, Dustin J.
Sax, Paul E.
Tierney, Camlin
Daar, Eric S.
Collier, Ann C.
Losina, Elena
Freedberg, Kenneth A.
Impact of Medication Adherence on Virologic Failure in A5202: A Randomized, Partially Blinded, Phase 3B Study
title Impact of Medication Adherence on Virologic Failure in A5202: A Randomized, Partially Blinded, Phase 3B Study
title_full Impact of Medication Adherence on Virologic Failure in A5202: A Randomized, Partially Blinded, Phase 3B Study
title_fullStr Impact of Medication Adherence on Virologic Failure in A5202: A Randomized, Partially Blinded, Phase 3B Study
title_full_unstemmed Impact of Medication Adherence on Virologic Failure in A5202: A Randomized, Partially Blinded, Phase 3B Study
title_short Impact of Medication Adherence on Virologic Failure in A5202: A Randomized, Partially Blinded, Phase 3B Study
title_sort impact of medication adherence on virologic failure in a5202: a randomized, partially blinded, phase 3b study
topic Brief Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5434358/
https://www.ncbi.nlm.nih.gov/pubmed/28329243
http://dx.doi.org/10.1093/cid/cix176
work_keys_str_mv AT parkerroberta impactofmedicationadherenceonvirologicfailureina5202arandomizedpartiallyblindedphase3bstudy
AT rabideaudustinj impactofmedicationadherenceonvirologicfailureina5202arandomizedpartiallyblindedphase3bstudy
AT saxpaule impactofmedicationadherenceonvirologicfailureina5202arandomizedpartiallyblindedphase3bstudy
AT tierneycamlin impactofmedicationadherenceonvirologicfailureina5202arandomizedpartiallyblindedphase3bstudy
AT daarerics impactofmedicationadherenceonvirologicfailureina5202arandomizedpartiallyblindedphase3bstudy
AT collierannc impactofmedicationadherenceonvirologicfailureina5202arandomizedpartiallyblindedphase3bstudy
AT losinaelena impactofmedicationadherenceonvirologicfailureina5202arandomizedpartiallyblindedphase3bstudy
AT freedbergkennetha impactofmedicationadherenceonvirologicfailureina5202arandomizedpartiallyblindedphase3bstudy

Ejemplares similares